293
New research underscores benefits of gender-affirming hormones, rebutting anti-trans claims
(www.statnews.com)
this post was submitted on 23 Jun 2023
293 points (100.0% liked)
World News
22059 readers
78 users here now
Breaking news from around the world.
News that is American but has an international facet may also be posted here.
Guidelines for submissions:
- Where possible, post the original source of information.
- If there is a paywall, you can use alternative sources or provide an archive.today, 12ft.io, etc. link in the body.
- Do not editorialize titles. Preserve the original title when possible; edits for clarity are fine.
- Do not post ragebait or shock stories. These will be removed.
- Do not post tabloid or blogspam stories. These will be removed.
- Social media should be a source of last resort.
These guidelines will be enforced on a know-it-when-I-see-it basis.
For US News, see the US News community.
This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.
founded 2 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
There is no practical way to blind HRT treatment. Even if you attempt to with a placebo, within about two weeks the patient will know what they are receiving.
Anybody demanding a double-blind study is trying to set the standard for evidence higher than is possible.
Exactly. Some things just can't be studied as part of a double blind RCT. For example, see: Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials
The paper is funny, but the authors are making a serious point. RCTs are great when they're possible, but just because they're not possible doesn't mean we can't gather strong evidence anyway.
Thank you for that paper, that's a great analogy honestly.
Thanks for that.
Lack of blinding is a serious issue for subjective outcomes but blinding when treatment effects are obvious to both intervention and control groups is dishonest (Pharma does it all the time to make their trials look more credible than they are).
Open label is the norm for cancer trials for exactly this reason. It is important to consider the biases that may arise, in subjective endpoints especially. But it is ludicrous to dismiss research on this basis alone. We can't randomise 12 year olds to become lifetime smokers or not, let alone use placebo controls, but we do know that smoking kills. It's just a bit more complicated to prove it when perfectly designed RCTs are not possible.